About lecnmab
Amyloid beta-directed monoclonal antibody
Used for
- Treats early Alzheimer’s disease, including mild cognitive impairment or mild dementia, with confirmed amyloid plaques.
Usual adult dose
Intravenous infusion every two weeks initially; after 18 months, maintenance may be every four weeks.
Common side effects
- Infusion-related reactions
- Brain swelling or bleeding (ARIA)
- Headache
- Falls
Important warnings
- ARIA can be serious or life-threatening; brain MRI monitoring is required.
- Risk of ARIA is higher in people with two APOE ε4 gene copies.
- Use caution with anticoagulants or medicines affecting clotting.
- Treatment is for early Alzheimer’s disease with confirmed amyloid pathology.
Pregnancy
Human pregnancy data are insufficient; potential fetal harm is unknown.
Breastfeeding
It is unknown whether lecanemab passes into breast milk or affects a nursing infant.
Interactions
- Anticoagulants and clot-affecting medicines may increase bleeding concerns, especially with ARIA.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.